MedTrace Logo

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

NCT06602232 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2026-05-12

No results posted yet for this study

Summary

This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.

Conditions

Interventions

DRUG

DR-01

DR-01 will be administered via IV infusion.

Sponsors & Collaborators

  • Dren Bio

    lead INDUSTRY

Principal Investigators

  • Michael Rothenberg, MD, PhD · Dren Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06602232 on ClinicalTrials.gov